The tricky economics of subsidising psychedelics for mental health therapy - The Conversation
1 May 2023
L-R: Professor Chris Langmead, Professor Cathy Mihalopoulos, Mary Lou Catterton
Director of the NDC Professor Chris Langmead, along with Professor Cathy Mihalopoulos and Mary Lou Catterton has written an article for The Conversation on the tricky economics of subsidising psychedelics for mental health therapy.
Extract from the article:
Australia is the world’s first country to legalise the medical use of psychedelics. But not everyone is sure the timing is right. There are still major issues to work out for this move to benefit those most in need.
In particular, there is the question of whether psychedelic medicines will be publicly subsidised, given the lack of data about their cost-effectiveness compared with other treatments.